1. Home
  2. PAI vs CRDL Comparison

PAI vs CRDL Comparison

Compare PAI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Income Fund Inc.

PAI

Western Asset Investment Grade Income Fund Inc.

N/A

Current Price

$12.18

Market Cap

118.3M

Sector

Finance

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.09

Market Cap

97.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAI
CRDL
Founded
1973
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.3M
97.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PAI
CRDL
Price
$12.18
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
15.5K
312.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.41
$0.77
52 Week High
$13.22
$1.59

Technical Indicators

Market Signals
Indicator
PAI
CRDL
Relative Strength Index (RSI) 27.76 59.91
Support Level $12.10 $0.95
Resistance Level $12.61 $1.10
Average True Range (ATR) 0.13 0.04
MACD -0.06 0.00
Stochastic Oscillator 4.94 88.74

Price Performance

Historical Comparison
PAI
CRDL

About PAI Western Asset Investment Grade Income Fund Inc.

Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: